TWI790672B - 拉索昔芬（lasofoxifene）之乳癌治療 - Google Patents

拉索昔芬（lasofoxifene）之乳癌治療 Download PDF

Info

Publication number
TWI790672B
TWI790672B TW110124571A TW110124571A TWI790672B TW I790672 B TWI790672 B TW I790672B TW 110124571 A TW110124571 A TW 110124571A TW 110124571 A TW110124571 A TW 110124571A TW I790672 B TWI790672 B TW I790672B
Authority
TW
Taiwan
Prior art keywords
patient
lasofoxifene
inhibitor
administered
certain embodiments
Prior art date
Application number
TW110124571A
Other languages
English (en)
Chinese (zh)
Other versions
TW202137980A (zh
Inventor
凱特琳 安德雷亞諾
靜宜 張
唐諾德 Ｐ 麥克唐奈
史黛芬妮 Ｌ 蓋拉德
Original Assignee
公爵大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 公爵大學 filed Critical 公爵大學
Publication of TW202137980A publication Critical patent/TW202137980A/zh
Application granted granted Critical
Publication of TWI790672B publication Critical patent/TWI790672B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
TW110124571A 2016-10-11 2017-10-11 拉索昔芬（lasofoxifene）之乳癌治療 TWI790672B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662406859P 2016-10-11 2016-10-11
US62/406,859 2016-10-11
US201762457759P 2017-02-10 2017-02-10
US62/457,759 2017-02-10
US201762502299P 2017-05-05 2017-05-05
US62/502,299 2017-05-05

Publications (2)

Publication Number Publication Date
TW202137980A TW202137980A (zh) 2021-10-16
TWI790672B true TWI790672B (zh) 2023-01-21

Family

ID=60186386

Family Applications (4)

Application Number Title Priority Date Filing Date
TW110124571A TWI790672B (zh) 2016-10-11 2017-10-11 拉索昔芬（lasofoxifene）之乳癌治療
TW111149243A TWI836808B (zh) 2016-10-11 2017-10-11 拉索昔芬（ｌａｓｏｆｏｘｉｆｅｎｅ）之乳癌治療
TW106134805A TWI729227B (zh) 2016-10-11 2017-10-11 拉索昔芬（lasofoxifene）之乳癌治療
TW113106582A TWI896001B (zh) 2016-10-11 2017-10-11 拉索昔芬（lasofoxifene）之乳癌治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
TW111149243A TWI836808B (zh) 2016-10-11 2017-10-11 拉索昔芬（ｌａｓｏｆｏｘｉｆｅｎｅ）之乳癌治療
TW106134805A TWI729227B (zh) 2016-10-11 2017-10-11 拉索昔芬（lasofoxifene）之乳癌治療
TW113106582A TWI896001B (zh) 2016-10-11 2017-10-11 拉索昔芬（lasofoxifene）之乳癌治療

Country Status (20)

Country Link
US (8) US20180098963A1 (cg-RX-API-DMAC7.html)
EP (2) EP4035662A1 (cg-RX-API-DMAC7.html)
JP (4) JP6892151B2 (cg-RX-API-DMAC7.html)
KR (5) KR102623130B1 (cg-RX-API-DMAC7.html)
CN (3) CN112353796A (cg-RX-API-DMAC7.html)
AU (3) AU2017360365B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019007254A2 (cg-RX-API-DMAC7.html)
CA (1) CA3040266A1 (cg-RX-API-DMAC7.html)
DK (1) DK3525774T3 (cg-RX-API-DMAC7.html)
ES (1) ES2909576T3 (cg-RX-API-DMAC7.html)
IL (2) IL284875B (cg-RX-API-DMAC7.html)
MX (2) MX387856B (cg-RX-API-DMAC7.html)
NZ (2) NZ752443A (cg-RX-API-DMAC7.html)
PL (1) PL3525774T3 (cg-RX-API-DMAC7.html)
PT (1) PT3525774T (cg-RX-API-DMAC7.html)
RU (1) RU2019114079A (cg-RX-API-DMAC7.html)
SG (2) SG10201913951YA (cg-RX-API-DMAC7.html)
TW (4) TWI790672B (cg-RX-API-DMAC7.html)
WO (2) WO2018093484A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201902454B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11974983B2 (en) 2018-04-10 2024-05-07 Duke University Lasofoxifene treatment of breast cancer
US11980597B2 (en) 2016-10-11 2024-05-14 Duke University Lasofoxifene treatment of breast cancer
US12023321B2 (en) 2021-11-18 2024-07-02 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of aromatase-resistant ER+cancer

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CN119947719A (zh) * 2022-05-25 2025-05-06 瑟默尼克斯制药公司 拉索昔芬联合治疗cdk4/6抑制剂治疗后进展的er+乳腺癌
WO2025075631A1 (en) 2023-10-06 2025-04-10 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of endocrine therapy resistant er+ cancer
WO2025099482A1 (en) * 2023-11-06 2025-05-15 Centro De Investigación Y De Estudios Avanzados Del I.P.N. Synergistic loratadine-raloxifene-sorafenib compositions for the treatment of hepatic cancer
WO2025122504A1 (en) * 2023-12-04 2025-06-12 Foundation Medicine, Inc. Esr1 mutations, esr1 co-occurring mutations, and uses thereof
WO2025165887A1 (en) * 2024-01-30 2025-08-07 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of er+ cancers with constitutively active esr1 mutations
CN119842900A (zh) * 2025-01-17 2025-04-18 厦门飞朔生物技术有限公司 一种可用于乳腺癌内分泌耐药治疗指导的人esr1基因突变检测试剂盒

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
WO1999065498A1 (en) 1998-06-19 1999-12-23 Senju Pharmaceutical Co., Ltd. Agents for relieving side effects of adrenal cortex hormone
YU26700A (sh) 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
EP1086692A3 (en) 1999-07-28 2003-07-09 Pfizer Products Inc. Estrogen agonists and antagonists for multiple indications
US6436977B1 (en) 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
PL357163A1 (en) 2000-01-28 2004-07-26 Endorecherche, Inc. Selective estrogen receptor modulators in combination with estrogens
DE10039199A1 (de) 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
PT1318837E (pt) 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
WO2002056903A2 (en) 2001-01-17 2002-07-25 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
HUP0500025A3 (en) 2002-03-28 2005-10-28 Pfizer Prod Inc Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
SG155258A1 (en) 2004-10-20 2009-09-30 Endorech Inc Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausa
US20090012052A1 (en) 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
US20110015134A1 (en) 2007-04-16 2011-01-20 Retsky Michael W Method of treatment for early stage cancer
CZ2007373A3 (cs) 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
US20110182888A1 (en) 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
EA018907B1 (ru) 2009-01-30 2013-11-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Кристаллический гидрохлорид n-{(1s)-2-амино-1-[(3-фторфенил)метил]этил}-5-хлор-4-(4-хлор-1-метил-1h-пиразол-5-ил)-2-тиофенкарбоксамида
EP2239570A1 (en) * 2009-04-10 2010-10-13 PamGene B.V. Method for determining the estrogen receptor status of breast cancer
WO2010138758A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
EP2606130B1 (en) 2010-08-16 2019-03-13 Duke University Camkk-beta as a marker in prostate cancer
US20120052508A1 (en) * 2010-08-27 2012-03-01 Rutgers, The State University Of New Jersey Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
JP2014516964A (ja) 2011-05-18 2014-07-17 メルク・シャープ・アンド・ドーム・コーポレーション 治療用抗ｉｇｆ１ｒ合剤
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
MD20140054A2 (ro) 2011-12-16 2014-10-31 Olema Pharmaceuticals, Inc. Compuşi noi de benzopiran, compoziţii şi utilizări ale acestora
US20160038506A1 (en) 2012-02-14 2016-02-11 Repros Therapeutics Inc. Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9204286B1 (en) 2013-03-15 2015-12-01 Sprint Communications Company L.P. System and method of branding and labeling a mobile device
KR20160132029A (ko) * 2014-03-13 2016-11-16 에프. 호프만-라 로슈 아게 에스트로젠 수용체 돌연변이체의 조절을 위한 방법 및 조성물
KR20160124909A (ko) 2014-03-13 2016-10-28 에프. 호프만-라 로슈 아게 에스트로겐 수용체 조절제를 함유하는 치료 조합물
FI3122426T3 (fi) 2014-03-28 2023-03-31 Univ Duke Rintasyövän hoitaminen käyttäen selektiivisiä estrogeenin reseptorin modulaattoreita
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CN111956653B (zh) 2014-05-08 2023-06-30 上海市生物医药技术研究院 双炔失碳酯组合物和疾病治疗方法
EP3215137A1 (en) 2014-11-07 2017-09-13 Lipoxen Technologies Limited Method for treatment of primary hormone resistant endometrial and breast cancers
AU2016247674A1 (en) 2015-04-14 2017-10-19 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders
RU2747228C2 (ru) * 2015-04-29 2021-04-29 Радиус Фармасьютикалз, Инк. Способы лечения рака
JP6892151B2 (ja) 2016-10-11 2021-06-23 デューク ユニバーシティ Ｅｒ＋乳がんのラソフォキシフェン処置
WO2018071437A1 (en) 2016-10-11 2018-04-19 Sermonix Pharmaceuticals, Llc Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies
CN115737637A (zh) 2017-01-10 2023-03-07 王巍 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
WO2019199891A1 (en) 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
CN113490850B (zh) * 2018-08-17 2024-12-06 基因泰克公司 用于治疗乳腺癌的诊断和治疗方法
JP2024538689A (ja) 2021-10-05 2024-10-23 デューク ユニバーシティ 腫瘍免疫の小分子制御因子を含む組成物及びその使用方法
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
CN119947719A (zh) 2022-05-25 2025-05-06 瑟默尼克斯制药公司 拉索昔芬联合治疗cdk4/6抑制剂治疗后进展的er+乳腺癌

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Andrea Z Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women J Natl Cancer Inst 102 J Natl Cancer Inst 2010 1706-1715

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980597B2 (en) 2016-10-11 2024-05-14 Duke University Lasofoxifene treatment of breast cancer
US12414924B2 (en) 2016-10-11 2025-09-16 Duke University Lasofoxifene treatment of breast cancer
US11974983B2 (en) 2018-04-10 2024-05-07 Duke University Lasofoxifene treatment of breast cancer
US12023321B2 (en) 2021-11-18 2024-07-02 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of aromatase-resistant ER+cancer
US12433866B2 (en) 2021-11-18 2025-10-07 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of aromatase-resistant ER+ cancer

Also Published As

Publication number Publication date
WO2018071440A1 (en) 2018-04-19
US10905659B2 (en) 2021-02-02
JP2024026527A (ja) 2024-02-28
RU2019114079A (ru) 2020-11-13
KR20220151017A (ko) 2022-11-11
US20240366534A1 (en) 2024-11-07
PL3525774T3 (pl) 2022-04-25
US20230233490A1 (en) 2023-07-27
CN110099680A (zh) 2019-08-06
KR102285453B1 (ko) 2021-08-05
AU2022246480B2 (en) 2024-11-07
CN112353796A (zh) 2021-02-12
TW202313005A (zh) 2023-04-01
JP7247241B2 (ja) 2023-03-28
TW202137980A (zh) 2021-10-16
TWI896001B (zh) 2025-09-01
EP3525774B1 (en) 2021-12-29
US20180098963A1 (en) 2018-04-12
DK3525774T3 (da) 2022-03-14
MX387856B (es) 2025-03-19
AU2017360365B2 (en) 2022-08-04
KR20210096316A (ko) 2021-08-04
KR102623130B1 (ko) 2024-01-10
TWI729227B (zh) 2021-06-01
NZ752443A (en) 2022-11-25
TW201817422A (zh) 2018-05-16
TWI836808B (zh) 2024-03-21
JP7418052B2 (ja) 2024-01-19
US12414924B2 (en) 2025-09-16
US11980597B2 (en) 2024-05-14
WO2018093484A1 (en) 2018-05-24
US10258604B2 (en) 2019-04-16
KR20230042390A (ko) 2023-03-28
US20210361596A1 (en) 2021-11-25
BR112019007254A2 (pt) 2019-07-02
KR102531354B1 (ko) 2023-05-11
MX2021013911A (es) 2022-01-18
NZ793063A (en) 2025-09-26
IL284875A (en) 2021-08-31
SG11201903236SA (en) 2019-05-30
RU2019114079A3 (cg-RX-API-DMAC7.html) 2021-07-23
AU2017360365A1 (en) 2019-05-02
US20180221335A1 (en) 2018-08-09
EP4035662A1 (en) 2022-08-03
CA3040266A1 (en) 2018-05-24
KR20190092377A (ko) 2019-08-07
US20190231718A1 (en) 2019-08-01
JP2023033415A (ja) 2023-03-10
AU2022246480A1 (en) 2022-12-08
IL265938B (en) 2021-08-31
US20190151286A1 (en) 2019-05-23
KR20240007720A (ko) 2024-01-16
MX2019004184A (es) 2019-09-27
JP6892151B2 (ja) 2021-06-23
CN112933082A (zh) 2021-06-11
ES2909576T3 (es) 2022-05-09
AU2025200327A1 (en) 2025-02-06
JP2019529581A (ja) 2019-10-17
JP2021073316A (ja) 2021-05-13
JP7774896B2 (ja) 2025-11-25
EP3525774A1 (en) 2019-08-21
TW202446367A (zh) 2024-12-01
SG10201913951YA (en) 2020-03-30
KR102462433B1 (ko) 2022-11-03
ZA201902454B (en) 2022-09-28
IL284875B (en) 2022-07-01
CN110099680B (zh) 2021-02-05
PT3525774T (pt) 2022-03-30
US20250064757A1 (en) 2025-02-27
IL265938A (en) 2019-05-30

Similar Documents

Publication Publication Date Title
JP7774896B2 (ja) Ｅｒ＋乳がんのラソフォキシフェン処置
HK40077706A (en) Lasofoxifene treatment of er+ breast cancer
HK40005311A (en) Lasofoxifene treatment of er+ breast cancer
HK40005311B (en) Lasofoxifene treatment of er+ breast cancer